Palliative care and hospice opioid dosing guidelines with breakthrough pain (BP) doses

American Journal of Hospice and Palliative Medicine

Volumn 17, Issue 6, 2000, Pages 407-413

  Pappagallo, Marco ^a   Dickerson, E Duke ^b   Hulka, Scott ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Oxford International Centre of Palliative Care   (United States)

^c Roxane Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NARCOTIC ANALGESIC AGENT;

DRUG ADMINISTRATION; HOSPICE CARE; HOSPITALIZATION; HUMAN; METHODOLOGY; NEOPLASM; PAIN; PAIN ASSESSMENT; PALLIATIVE THERAPY; PRACTICE GUIDELINE; REVIEW; STANDARD; TREATMENT OUTCOME;

ANALGESICS, OPIOID; DRUG ADMINISTRATION SCHEDULE; HOSPICE CARE; HUMANS; NEOPLASMS; PAIN; PAIN MEASUREMENT; PALLIATIVE CARE; PRACTICE GUIDELINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0034334098     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/104990910001700612     Document Type: Article

References (21)

1. Lipman AG: Clinically relevant differences among the opioid analgesics. American Journal of Hospital Pharmacy. 1990; 47(58): S7-S13.
2. Ross FB, Smith MT: The intrinsic anti-nociceptive effects of oxycodone appear to be kappa opioid receptor mediated. Pain. 1997; 73: 151-157.
3. Ross FB, Wallis SC, Smith MT: Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats. Pain. 2000; 84: 421-428.
4. Coyle N, Adelhardt J, Foley KM, Portenoy RK: Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. Journal of Pain and Symptom Management. 1990; 5(2): 83-93.
5. Faisinger R, Bruera E, et al.: Symptom control during the last week of life on a palliative care unit. Journal of Palliative Care. 1991; 7(1): 5-11.
6. US Department of Health and Human Services. Management of Cancer Pain, Number 9. AHCPR Publication No. 94-0592, March 1994.
7. Mercadante S: Costs Are a Further Barrier to Cancer Pain Management. Journal of Pain and Symptom Management. 1999;
8. Portenoy RK, Lesage P: Management of Cancer Pain. Lancet. 1999; 353: 1695-1700.
9. Heiskanen T, Kalso E: Controlled-release oxycodone and morphine in cancer related pain. Pain. 1997; 73(1): 37-45.
10. Portenoy RK, Hagen NA: Breakthrough pain: Definition, prevalence and characteristics. Pain. 1990; 41: 273-281.
11. Simmonds MA: Management of breakthrough pain due to cancer. Oncology. 1999; 13(8): 1103-1108.
12. Fine PG, Busch MA: Characterization of breakthrough pain by hospice patients and their caregivers. Journal of Pain and Symptom Management. 1998; 16(3): 179-183.
13. Patt RB, Ellison NM: Breakthrough pain in cancer patients: Characteristics, prevalence and treatment. Oncology. 1998; 12(7): 1035-1046.
14. Cherny N, Portenoy RK: Cancer pain management. Cancer. 1993; 72: 3393-3415.
15. Glare PA, Walsh TD: Dose-ranging study of oxycodone for chronic pain in advanced cancer. Journal of Clinical Oncology. 1993; 11(5): 973-978.
16. Portenoy RK: Analgesic Ladder for the Management of Cancer Pain. New York: The McMahon Group, 1995.
17. World Health Organization. Cancer Pain Relief. Geneva: World Health Organization, 1986.
18. Cherny NI: Opioid Analgesics: Comparative features and prescribing Guidelines. Drugs. 1996; 51(5): 713-737.
19. Twycross R, Wilcock A, Thorp S: Palliative Care Formulary. Oxford: Radcliffe Medical Press, 1998.
20. Ripamonti C, Groff L, Brunelli C, et al.: Switching from morphine to oral methadone in treating cancer pain: What is the equianalgesic dose ratio? Journal of Clinical Oncology. 1998; 16(10): 3216-3221.
21. Zhukovsky DS, Walsh D, Doona M: The relative potency between high dose oral oxycodone and intravenous morphine: A case illustration. Journal of Pain and Symptom Management. 1999; 18: 53-55.